<DOC>
	<DOCNO>NCT02142777</DOCNO>
	<brief_summary>The purpose study determine S-equol could benefit person Alzheimer 's Disease ( AD ) .</brief_summary>
	<brief_title>S-Equol Alzheimer 's Disease ( SEAD ) Trial</brief_title>
	<detailed_description>Alzheimer 's disease ( AD ) progressive brain disorder cause memory think problem . The exact cause AD unknown . Researchers believe mitochondrion ( part cell produce energy ) might link symptom AD . Some study show patient Alzheimer 's disease reduce mitochondrial activity few mitochondrion present neuron . In study , believe target mitochondrion , might learn influence AD symptom . Mitochondria receptor site estrogen ( hormone ) call estrogen receptor β ( ERβ ) . When estrogen attach site , promote mitochondrial function . Studies also suggest ERβ stimulation cause cell create new mitochondrion . More mitochondrion , increase activity exist mitochondrion , cell might impact patient Alzheimer 's disease . One way measure increase function look presence enzyme call COX blood . If drug increase mitochondrial function , increase COX concentration bloodstream . By study hope learn S-equol , compound act like estrogen body , cause increase mitochondrial activity . We also hope determine tolerability therapeutic dose S-equol . It goal advance understanding AD , particularly woman .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Equol</mesh_term>
	<criteria>Very mild ( CDR 0.5 ) mild ( CDR 1 ) AD time last KU ADC assessment Have study partner Speak English primary language No viable study partner Report potentially confound , serious medical risk type 1 diabetes , cancer , recent cardiac event ( i.e . heart attack , angioplasty , etc . ) Use type estrogen replacement therapy</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>S-equol</keyword>
	<keyword>COX activity</keyword>
</DOC>